methyl 6-benzamidohexanoate | 32039-15-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 6-benzamidohexanoate
• CAS: 32039-15-9
• 化学式: C₁₄H₁₉NO₃
• mdl: MFCD00995419
• 分子量: 249.31
• InChiKey: VQSANGBWDQQOFP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 6-benzamidohexanoate 在 lithium hydroxide 、 TEA 、 双(2-氧代-3-恶唑烷基)次磷酰氯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 N-benzyloxy-6-(4-benzoyl)aminocapramide
  参考文献：
  名称：

  Amide Analogues of Trichostatin A as Inhibitors of Histone Deacetylase and Inducers of Terminal Cell Differentiation

  摘要：

  Inhibitors of histone deacetylase (HD) bear great potential as new drugs due to their ability to modulate transcription and to induce apoptosis or differentiation in cancer cells. We have described previously analogues of the complex natural HD inhibitors trapoxin B and trichostatin A with activities in the submicromolar range. Here we report structure-activity relationship analyses of further analogues of trichostatin A with respect to in vitro inhibition of maize HD-2 and their ability to induce terminal cell differentiation in Friend leukemic cells. This is the first report that shows the correlation between HD inhibitory activity and action on cancer cells on a larger series of similar compounds. Only the compounds that inhibit HD induce differentiation and/or exert antiproliferative activities in cell culture. Our studies support the use of in vitro systems as screening tools and provide structure-activity relationships that merit further investigation of this interesting target.

  DOI：

  10.1021/jm991091h
• 作为产物：
  描述：

  1-methoxy-1-hydroperoxycyclohexane 在 三乙烯二胺 、 copper(l) iodide 、 1,10-菲罗啉 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 1.5h， 生成 methyl 6-benzamidohexanoate
  参考文献：
  名称：

  通过从甲硅烷基过氧缩醛生成烷基自由基合成官能化脂肪酸酯

  摘要：

  描述了使用甲硅烷基过氧缩醛作为具有末端酯部分的烷基自由基前体获得官能化脂肪酸酯的催化方法。该反应通过烷基自由基的原位生成和随后的官能化进行，得到具有合成价值的脂肪酸衍生物。还开发了一种通过 CO 键形成过程合成羟基酸衍生物的新策略。

  DOI：

  10.1002/asia.202100723

文献信息

• Chemoselective Reductive Nucleophilic Addition to Tertiary Amides, Secondary Amides, and<i>N</i>-Methoxyamides
  作者：Minami Nakajima、Yukiko Oda、Takamasa Wada、Ryo Minamikawa、Kenji Shirokane、Takaaki Sato、Noritaka Chida

  DOI：10.1002/chem.201404648

  日期：2014.12.22

  modern organic synthesis, chemoselectivity is recognized as an important factor in the development of new methodologies. Chemoselective nucleophilic addition to amide carbonyl centers is a challenge because classical methods require harsh reaction conditions to overcome the poor electrophilicity of the amide carbonyl group. We have successfully developed a reductive nucleophilic addition of mild nucleophiles

  随着目标分子在现代有机合成中的复杂性增加，化学选择性被认为是开发新方法的重要因素。酰胺羰基中心的化学选择性亲核加成是一个挑战，因为经典方法需要苛刻的反应条件以克服酰胺羰基的不良亲电性。我们已经成功开发出使用Schwartz试剂将温和的亲核试剂还原性添加到叔酰胺，仲酰胺和N-甲氧基酰胺上的亲核试剂[Cp 2ZrHCl]。该反应在各种敏感的官能团，例如甲酯的存在下，以高度化学选择性的方式发生，这些官能团通常需要在亲核加成之前进行保护。该反应将适用于由容易获得的酰胺基团简单合成复杂的天然生物碱。
• Neuartige massenspektrometrische Zerfallsreaktionen bei ?,?-disubstituierten Alkanen. 15. Mitteilung �ber das massenspektrometrische verhalten von stickstoffverbindungen [1]
  作者：H. J. Veith、A. Guggisberg、M. Hesse

  DOI：10.1002/hlca.19710540224

  日期：——

  The mass spectral behaviour of α,ω-disubstituted alkanes and, especially, that of different N-substituted α,ω-diaminoalkanes has been investigated. It was found that the two amino groups which are separated by CH2-groups can fragment only to a small extent indepently from each other. Yet those fragmentation reactions are predominant in which both functional groups participate. The main reactions of

  研究了α，ω-二取代烷烃的质谱行为，尤其是不同的N-取代的α，ω-二氨基烷烃的质谱行为。发现被CH 2-基团隔开的两个氨基只能在很小的程度上彼此独立地断裂。然而，这些断裂反应主要是两个官能团都参与其中。这种类型的主要反应是：
• [EN] COMPOUNDS FOR TREATMENT OF GLIOBLASTOMA<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DU GLIOBLASTOME
  申请人：UNIV ALBERTA

  公开号：WO2018132905A1

  公开（公告）日：2018-07-26

  The present invention relates to compounds and methods for the treatment of glioblastoma, as well as to a pharmaceutical composition comprising said compounds. More specifically the invention relates to substituted quinoline derivatives having the formula (I), (II) or (III), and a pharmaceutical composition comprising said compounds for the treatment of cancer. (Formulae (I), (II), (III))

  本发明涉及用于治疗胶质母细胞瘤的化合物和方法，以及包含该化合物的药物组合物。更具体地，本发明涉及具有化学式(I)、(II)或(III)的取代喹啉衍生物，以及包含该化合物的药物组合物，用于治疗癌症。
• COMPOUNDS AND USE FOR TREATING CANCER
  申请人：GLIONOVA AB

  公开号：US20160214958A1

  公开（公告）日：2016-07-28

  The present invention relates to certain 2,4-disubstituted quinoline derivatives, to their therapy, as well as to pharmaceutical compositions comprising said compounds. More specifically the invention relates to certain 2,4-disubstituted quinoline derivatives or pharmaceutical compositions comprising said compounds for the treatment of cancers characterized by overactive Ras and/or Rac or signalling pathway.

  本发明涉及某些2,4-二取代喹啉衍生物及其治疗方法，以及包含该化合物的制药组合物。更具体地说，本发明涉及某些2,4-二取代喹啉衍生物或包含该化合物的制药组合物，用于治疗由过度活跃的Ras和/或Rac或信号通路所特征的癌症。
• CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS
  申请人：Watkins Clare J.

  公开号：US20110105572A1

  公开（公告）日：2011-05-05

  This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: wherein: A is a C 5-20 heteroaryl or C 5-20 carboaryl group and is optionally substituted; Q 1 is a C 2-7 alkylene group having a backbone of at least 2 carbon atoms, and is optionally substituted; J is —N(R 1 )C(═O)— or —C(═O)N(R 1 )—; R 1 is hydrogen, C 1-7 alkyl, C 3-20 heterocyclyl, or C 5-20 aryl; and, Q 2 is C 1-7 alkylene, C 5-20 arylene, C 5-20 arylene-C 1-7 alkylene, or C 1-7 alkylene-C 5-20 arylene having a backbone of at least 3 carbon atoms, and is optionally substituted; and pharmaceutically acceptable salts thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to treat proliferative conditions, such as cancer and psoriasis.

  本发明涉及某些活性碳酰胺酸化合物，其抑制HDAC活性，并具有以下公式：其中：A是C5-20杂环芳基或C5-20羰基芳基基团，并可选择性地取代；Q1是具有至少2个碳原子的C2-7烷基链，可选择性地取代；J是-N（R1）C（═O）-或-C（═O）N（R1）-；R1是氢，C1-7烷基，C3-20杂环芳基或C5-20芳基；Q2是具有至少3个碳原子的C1-7烷基链，C5-20芳基链，C5-20芳基链-C1-7烷基链，或C1-7烷基链-C5-20芳基链，并可选择性地取代；以及其药学上可接受的盐。本发明还涉及包含这种化合物的制药组合物，以及使用这种化合物和组合物在体内外抑制HDAC，例如治疗增殖性疾病，如癌症和牛皮癣。